Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) has received a "Moderate Buy" consensus rating from analysts, with an average 1-year price target of $93.38. Several firms recently raised their price targets for PTGX. Despite some insider selling, institutional ownership remains high at 98.63%, and the company specializes in developing orally administered peptide-based therapies for immune-mediated diseases.
Protagonist Therapeutics (NASDAQ:PTGX) Director Lewis Williams Sells 18,000 Shares
Protagonist Therapeutics (NASDAQ:PTGX) Director Lewis Williams sold 18,000 shares of the company's stock, valued at over $1.48 million, on February 17th, reducing his stake by nearly 70%. Despite the insider sale, analysts maintain a "Moderate Buy" consensus rating with an average price target of $93.38, and the stock is trading around $82.99 with a market cap of $5.19 billion. The company is a clinical-stage biopharmaceutical firm focused on orally administered peptide-based therapies.
Protagonist Therapeutics director Williams sells $1.48 million in shares
Protagonist Therapeutics director Lewis T. Williams sold 18,000 shares of common stock for $1.48 million on February 17, 2026, after exercising options to acquire the same number of shares. Following these transactions, Williams directly owns 7,825 shares. The company has recently received positive analyst updates and price target increases from firms like H.C. Wainwright, Truist Securities, JPMorgan, Citizens, and Jefferies, noting progress on its lead assets, rusfertide and icotrokinra.
Protagonist Therapeutics Director Sells 18,000 Shares
Lewis T. Williams, a Director at Protagonist Therapeutics (PTGX), sold 18,000 shares of common stock on February 17, 2026, for a total of $1,483,560. The shares were sold at a weighted average price of $82.42, with prices ranging from $81.47 to $83.12. Following this transaction, Williams directly owns 7,825 shares in the company.
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Evaluating a 25% Upside Potential in the Biotech Sector
Protagonist Therapeutics (PTGX) is a biopharmaceutical company with a market capitalization of $5.09 billion, specializing in peptide therapeutics for various diseases. The company is currently trading at $81.49, with analysts projecting a 25.07% upside potential and an average target price of $101.92, supported by 11 buy ratings. Protagonist's pipeline includes promising candidates like Rusfertide in Phase 3 trials and Icotrokinra targeting injectable antibody drug pathways, positioning it for potential growth despite some short-term bearish technical indicators.
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
Protagonist Therapeutics director William D. Waddill sold 20,000 shares for $1.7 million after exercising stock options on February 6, 2026. This significant sale occurred during a period of strong stock performance, with the company's shares up 123.8% in the prior twelve months. Despite the director's sale, most Wall Street analysts maintain a "strong buy" rating for Protagonist Therapeutics, citing high growth expectations and advanced clinical trials backed by major pharmaceutical partners like Johnson & Johnson.
Protagonist Therapeutics Milestones Test Valuation As NDAs And Trials Advance
Protagonist Therapeutics (NasdaqGM:PTGX) is gaining market attention after submitting New Drug Applications (NDAs) for Icotrokinra and Rusfertide, and advancing Phase 3 trials with partners like Johnson & Johnson and Takeda. Despite significant multi-year returns, the stock has experienced recent short-term declines, presenting a mixed picture for investors. The company's valuation metrics, including a high P/E ratio relative to the biotech industry and recent insider selling, will be closely watched as regulatory decisions and clinical readouts unfold.
Protagonist Therapeutics (PTGX) to Release Earnings on Friday
Protagonist Therapeutics (NASDAQ:PTGX) is set to announce its Q4 2025 earnings before the market opens on Friday, February 20th, with analysts anticipating a loss of ($0.53) per share. Recent insider selling includes CFO Asif Ali and Director William D. Waddill, with insiders having sold approximately $15.4 million worth of shares in the past 90 days. Despite the insider sales, the company holds a "Moderate Buy" consensus rating from analysts, with an average price target of $91.64.
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy
H.C. Wainwright has increased its price target for Protagonist Therapeutics, Inc. (PTGX) to $117 from $80, maintaining a Buy rating. The firm based its decision on the company's strong drug development track record and the potential of its pipeline assets, including PN-8047 and obesity programs. Protagonist Therapeutics also anticipates multiple Phase 2 and Phase 3 readouts in immunology, hematology, and obesity, supported by existing partnerships.
H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy
H.C. Wainwright has increased its price target for Protagonist Therapeutics, Inc. (PTGX) to $117 from $80, reiterating a "Buy" rating. This decision is based on the company's strong drug development track record and the potential of its pipeline assets, including PN-8047 and obesity programs. Protagonist Therapeutics is advancing multiple late-stage assets and maintains partnerships with Johnson & Johnson and Takeda, providing non-dilutive funding.
Protagonist Therapeutics, Inc. (PTGX) Investor Outlook: Exploring a 22.32% Potential Upside Amidst Strong Buy Ratings
Protagonist Therapeutics, Inc. (PTGX) is gaining investor attention with its focus on peptide therapeutics for hematology and inflammatory diseases, highlighted by its pipeline featuring Rusfertide and Icotrokinra in phase 3 trials. Analysts express strong confidence, with 11 buy ratings and an average target price suggesting a 22.32% potential upside. Despite typical biotech challenges, the company's robust pipeline and positive analyst sentiment make it a compelling option for growth-seeking investors in the biopharmaceutical sector, though due diligence is advised.
Protagonist Therapeutics director sells $1.67 million in shares By Investing.com
A director at Protagonist Therapeutics (NASDAQ:PTGX), William D. Waddill, sold 20,000 shares of common stock for approximately $1.67 million while simultaneously exercising options to acquire an equal number of shares for $166,200. This transaction leaves him with 7,825 direct shares in the company. The article also highlights recent positive analyst updates and drug development milestones for Protagonist Therapeutics, indicating growing confidence in its future.
Insider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 20,000 Shares of Stock
Protagonist Therapeutics director William Waddill sold 20,000 shares of company stock for a total of $1,673,600, reducing his stake by 71.88%. The sale occurred on February 6th at an average price of $83.68 per share. Despite the insider selling, Protagonist Therapeutics' stock saw a 4.7% increase, trading at $84.49, and has an average analyst rating of "Moderate Buy" with a target price of $91.64.
Assessing Protagonist Therapeutics (PTGX) Valuation After Rusfertide NDA Filing And Rising Analyst Optimism
Protagonist Therapeutics (PTGX) is gaining attention following the NDA filing for rusfertide and increased analyst optimism, despite a high P/E ratio of 116.6x. While the P/E suggests overvaluation compared to peers, a Discounted Cash Flow (DCF) model indicates the stock is significantly undervalued at $85.59, suggesting a potential 74.3% discount to its estimated future cash flow value. The article advises investors to consider both earnings-based and cash flow-based valuations.
Assessing Protagonist Therapeutics (PTGX) Valuation After Rusfertide NDA Filing And Rising Analyst Optimism
Protagonist Therapeutics (PTGX) is gaining attention following its New Drug Application filing for rusfertide with Takeda and increased analyst optimism. Despite a high Price-to-Earnings ratio of 116.6x, suggesting overvaluation compared to peers, a Discounted Cash Flow model indicates the stock might be significantly undervalued, trading about 74.3% below its estimated future cash flow value. This discrepancy highlights differing valuation perspectives based on earnings versus cash flow.
Precision Trading with Protagonist Therapeutics Inc. (PTGX) Risk Zones
This article provides an in-depth analysis of Protagonist Therapeutics Inc. (PTGX) using AI models to identify risk zones and potential trading opportunities. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis and real-time entry/exit signals. The analysis suggests a shift from strong near-term positive sentiment to mid-term neutrality and then a long-term positive bias.
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Protagonist Therapeutics announced that its President and CEO, Dinesh V. Patel, Ph.D., will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. The presentation will be accessible via webcast, and the company will also engage in one-on-one meetings. Protagonist Therapeutics is a biopharmaceutical company with two novel peptides, icotrokinra and rusfertide, currently in advanced Phase 3 clinical development.
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Protagonist Therapeutics announced new clinical data for icotrokinra in moderate-to-severe plaque psoriasis from its Phase 3 ICONIC-ADVANCE and ICONIC-LEAD studies, demonstrating superior skin clearance and a favorable safety profile. Additionally, preclinical data for PN-881, a first-in-class oral peptide targeting the IL-17 pathway, were presented, showing strong in vitro potency and efficacy in an animal model. These presentations at the EADV 2025 Congress highlight Protagonist's advancements in developing oral peptide therapies for inflammatory and immunomodulatory diseases.
Jefferies Raises Price Target for PTGX to $118, Maintains 'Buy' Rating | PTGX Stock News
Jefferies has raised its price target for Protagonist Therapeutics (PTGX) to $118 from $95, maintaining a 'Buy' rating. This adjustment reflects a positive outlook, aligning with other analysts like HC Wainwright & Co. and Truist Securities, who have also increased their price targets for the biopharmaceutical company. Despite an average target price of $100.54 from 13 analysts, GuruFocus estimates a potential downside based on its GF Value model.
Should Insider Selling Amid Rusfertide Progress and Icotrokinra Advances Require Action From Protagonist Therapeutics (PTGX) Investors?
Protagonist Therapeutics is experiencing mixed signals for investors, with recent insider stock sales by senior executives alongside positive progress in its drug candidates, rusfertide and icotrokinra. While the insider sales are largely attributed to tax and option exercises and haven't deterred Wall Street analysts' optimism, the company's investment narrative primarily relies on the regulatory success and potential launch of its lead drugs. Investors are advised to consider the bigger risks of execution and safety in late-stage programs, as well as the current valuation, which may already reflect much of the good news.
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, sold 9,514 shares of PTGX stock for approximately $784,700 to cover taxes, marking his largest open-market sale to date. Despite the sale, which is considered a tax-related transaction and not indicative of company performance, Wall Street analysts maintain a "strong buy" rating for PTGX, citing high growth expectations and significant projected growth within the next 12-24 months. The company, which specializes in rare blood disorders and inflammatory diseases, saw its stock rise 123% in 2025 and anticipates further expansion with new clinical trial pipelines and advanced pharmaceutical products.
Protagonist Therapeutics CMO Sells Shares in Major Transaction
Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, sold 9,514 shares for approximately $784,700, his largest direct market sale to date, primarily for tax withholding purposes. Despite this, Molina retains significant holdings, and the company has shown strong financial performance with a 120.48% stock price increase over the last year. Wall Street analysts largely maintain a "strong buy" rating for PTGX, reflecting optimistic growth expectations, especially with its expanding clinical trial pipelines.
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Great Lakes Advisors LLC
Great Lakes Advisors LLC reduced its stake in Protagonist Therapeutics (NASDAQ: PTGX) by 36% in Q3, selling over 50,000 shares. Insiders, including Arturo Md Molina and CFO Asif Ali, have also been selling a significant number of shares recently. Despite insider selling, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and an average target price of $86.77.
Protagonist Therapeutics CEO Patel sells $4m in shares
Dinesh V. Patel, CEO of Protagonist Therapeutics (NASDAQ:PTGX), sold 48,205 shares totaling approximately $4 million, while also exercising options to acquire 48,273 shares. Following these transactions, Patel directly owns 574,505 shares. The company has also received multiple positive analyst ratings and price target increases, driven by promising pipeline developments for icotrokinra and rusfertide.
Protagonist Therapeutics CEO Patel sells $4m in shares
Dinesh V. Patel, CEO of Protagonist Therapeutics, sold over $4 million in company shares between January 23 and 27, 2026, while also exercising options to acquire additional shares. Following these transactions, Patel directly owns 574,505 shares. The company has recently received positive analyst attention with multiple firms raising price targets due to expected drug approvals and pipeline potential.
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $93
J.P. Morgan has reiterated its "Buy" rating for Protagonist Therapeutics (PTGX.US) and maintained its target price at $93. Analyst Brian Cheng, who has a 50.9% success rate and 1.3% average return over the past year, provided this assessment. The article highlights that TipRanks, an independent third party, provides the analysis data, with success rates and average returns calculated based on virtual portfolio performance.
JPMorgan reiterates Overweight rating on Protagonist Therapeutics stock
JPMorgan has reiterated its Overweight rating and $93.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) following a recent stock pullback. The valuation is largely driven by the anticipated launch of Icotyde, with a potential $5 billion enterprise value from a 10% royalty on peak sales, and the expected opt-out for Rusfertide which could add $1.5 billion to enterprise value and a $400 million payout. Analysts also highlight the oral IL-17 program and new obesity programs as future catalysts for the company.
Universal Beteiligungs und Servicegesellschaft mbH Raises Stock Position in Protagonist Therapeutics, Inc. $PTGX
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 123.1% in Q3, now owning 90,317 shares worth approximately $6.0 million. This move reflects a broader trend of high institutional ownership in the company, with 98.63% of the stock held by institutional investors, including major increases from firms like Adage Capital Partners and BVF Inc. Analysts maintain a "Moderate Buy" rating for Protagonist Therapeutics, with an average price target of $86.77, and recent target increases from Truist Financial and JPMorgan Chase & Co.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Thirteen analysts have given Protagonist Therapeutics, Inc. (NASDAQ:PTGX) a consensus "Moderate Buy" rating, with an average 12-month price target of $86.77. Despite this, the company recently missed earnings and revenue expectations, and insiders have been net sellers of the stock. Hedge funds and other institutional investors hold a significant portion of the company's shares.
A Look At Protagonist Therapeutics (PTGX) Valuation After Recent Insider Stock Sales By Top Executives
Recent insider stock sales at Protagonist Therapeutics (PTGX) by top executives, with no reported buying, coincide with a significant 6.4% stock pullback over 30 days, following a multi-year surge. While the company's P/E ratio of 113.2x suggests it is overvalued compared to industry averages and an estimated fair P/E of 32.5x, Simply Wall St's discounted cash flow (DCF) model indicates a fair value of $231.51 per share, considerably higher than its current trading price of $83.10. This discrepancy highlights a complex valuation challenge for investors.
Have Insiders Sold Protagonist Therapeutics Shares Recently?
Protagonist Therapeutics' CEO, President Dinesh Patel, recently sold US$2.8m worth of stock, representing 9.1% of his holding. This follows an earlier sale this year at a lower price. While there has been insider selling, no insider buying has occurred over the last year, suggesting caution for potential investors.
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Protagonist Therapeutics announced that its President and CEO, Dinesh V. Patel, Ph.D., will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference, scheduled from January 12-15, 2026, in San Francisco. The company will also hold one-on-one meetings during the event. Protagonist Therapeutics, a biopharmaceutical company, has two novel peptides in advanced Phase 3 clinical development, with NDA submissions for icotrokinra and rusfertide in July and December 2025, respectively.
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics announced that data from its Phase 2b ANTHEM-UC study for icotrokinra in ulcerative colitis will be presented at the United European Gastroenterology Week 2025 in Berlin. The presentation will feature week 12 results from the randomized, double-blind, placebo-controlled trial. Icotrokinra is an oral peptide that selectively blocks the IL-23 receptor, and its New Drug Application (NDA) was submitted to the FDA in July.
Have Insiders Sold Protagonist Therapeutics Shares Recently?
Protagonist Therapeutics' CEO, Dinesh Patel, recently sold a substantial US$2.8 million worth of stock, though this only represented 9.1% of his total holding. This follows an earlier sale this year at a lower price, indicating insiders have been selling but not buying shares in the last year. Despite some insider selling, the company's insiders still own 1.1% of the company, valued at US$56 million.
Have Insiders Sold Protagonist Therapeutics Shares Recently?
Protagonist Therapeutics' CEO, President Dinesh Patel, recently sold US$2.8m worth of shares, representing 9.1% of his holding. This follows an earlier sale this year at a lower price. While insiders haven't bought shares in the last year, they still own 1.1% of the company, valued at US$56m, suggesting some alignment with shareholder interests despite the selling activity.
Protagonist therapeutics CEO Patel sells $2.84 million in shares By Investing.com
Dinesh V. Patel, President and CEO of Protagonist Therapeutics, Inc. (NASDAQ:PTGX), sold 34,438 shares of common stock for $2.84 million to cover tax withholding obligations. While the stock has seen significant returns and the company maintains a strong financial position, it appears overvalued based on its Fair Value assessment. The company has several promising drug candidates with positive analyst outlooks and raised price targets.
Protagonist therapeutics CEO Patel sells $2.84 million in shares
Dinesh V. Patel, CEO of Protagonist Therapeutics (NASDAQ:PTGX), sold 34,438 shares worth $2.84 million to cover tax obligations. Despite this insider sale, the company maintains a strong financial position with more cash than debt and a "GREAT" financial health score, trading at a high P/E ratio. Analysts have an optimistic outlook, raising price targets and highlighting upcoming approvals for key assets like icotrokinra and rusfertide.
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $2,840,446.24 in Stock
Protagonist Therapeutics (NASDAQ:PTGX) CEO Dinesh Ph Patel sold 34,438 shares of the company's stock for a total of $2,840,446.24. This transaction reduced his ownership by 5.6%, leaving him with 580,505 shares valued at approximately $47.88 million. The company, a clinical-stage biopharmaceutical firm focusing on oral peptide therapies, has a consensus "Moderate Buy" rating from analysts with an average target price of $86.77.
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares
Protagonist Therapeutics (NASDAQ:PTGX) insider Arturo Md Molina sold 9,514 shares of the company's stock on January 20th, reducing his stake by 8.91%. The sale totaled $784,714.72 and leaves him with 97,266 shares. The company's stock traded up $0.47 on Wednesday, with a market capitalization of $5.24 billion and a consensus "Moderate Buy" rating from analysts.
Asif Ali Sells 8,588 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
Protagonist Therapeutics CFO Asif Ali sold 8,588 shares of PTGX stock for over $708,000, reducing his stake by 9.91%. Shares traded up 0.6% to $83.89, and the company has a market cap of $5.24 billion. Wall Street analysts maintain a "Moderate Buy" rating with an average target price of $86.77, while institutional investors own approximately 98.63% of the stock.
Protagonist therapeutics CEO Patel sells $2.84 million in shares
Protagonist Therapeutics CEO Dinesh V. Patel sold 34,438 shares for $2.84 million to cover tax obligations. Despite this insider sale, the company maintains a strong financial position and has received optimistic analyst price targets due to promising product developments and regulatory reviews. The stock has seen significant returns, though InvestingPro data suggests it may be overvalued.
Protagonist Therapeutics Executives Sell Shares to Cover Tax Obligations
Several executives at Protagonist Therapeutics (PTGX) recently sold company shares to cover tax obligations related to restricted stock units. CFO Ali Asif, President and CEO Dinesh V Patel Ph.D., and CMO Arturo Molina each sold significant amounts of stock. These transactions are detailed in SEC Form 4 filings, showing the number of shares sold and the total value, as well as their remaining direct holdings in the company.
H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Protagonist Therapeutics (PTGX) with a price target of $80.00. This comes despite a recent downgrade to Hold by TipRanks – Anthropic and negative corporate insider sentiment with increased selling activity. The company reported a slight increase in quarterly revenue but also a higher GAAP net loss compared to the previous year.
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Protagonist Therapeutics, Inc. announced that its President and CEO, Dinesh V. Patel, Ph.D., will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 13, 2026, at 8:15 AM PST. The company will also engage in one-on-one meetings during the conference, which runs from January 12-15, 2026, in San Francisco.
Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback
Protagonist Therapeutics (PTGX) has experienced a significant 132% return over the past year, though recent performance includes a 7% decline. Despite its current high P/E ratio of 115.4x, suggesting overvaluation compared to industry averages and an estimated fair P/E of 32.6x, a Discounted Cash Flow (DCF) model indicates the stock is trading 63.1% below its estimated fair value of US$229.86. Investors are encouraged to consider both valuation methods and build their own narrative based on assumptions about future trial outcomes and financial projections.
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
Protagonist Therapeutics, Inc. announced the submission of a New Drug Application (NDA) to the U.S. FDA for icotrokinra, an investigational oral peptide targeting moderate-to-severe plaque psoriasis in adults and adolescents. The submission is based on positive results from four Phase 3 studies, which demonstrated significant skin clearance and a favorable safety profile compared to placebo and deucravacitinib. Icotrokinra is designed to selectively block the IL-23 receptor and has the potential to expand into other inflammatory indications like psoriatic arthritis and ulcerative colitis.
With Two Partnered Launches Expected In 2026, Protagonist Looks To Next Chapter
Protagonist Therapeutics is anticipating two partnered drug launches in 2026, signaling a significant growth phase for the company. The article, published on January 14, 2026, highlights the company's forward-looking strategy. Key developments include advances in their pipeline, such as Takeda/Protagonist’s Rusfertide.
SG Americas Securities LLC Grows Stock Holdings in Protagonist Therapeutics, Inc. $PTGX
SG Americas Securities LLC significantly increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 2,043.8% during the third quarter, now holding 41,246 shares valued at approximately $2.74 million. Other hedge funds also adjusted their positions, and institutional investors collectively own 98.63% of the company's stock. Analysts generally maintain a "Moderate Buy" rating for PTGX, with a consensus price target of $86.77, despite the company recently missing Q3 earnings and revenue estimates.
Does Rusfertide’s FDA NDA Submission Redefine The Bull Case For Protagonist Therapeutics (PTGX)?
Protagonist Therapeutics and Takeda submitted a New Drug Application (NDA) to the FDA for rusfertide, a potential treatment for polycythemia vera, supported by positive Phase 2 and 3 trial results. This submission is a significant catalyst, shifting the investment focus from trial execution to regulatory review, though elevated expectations mean the market may be sensitive to any delays. The article suggests evaluating the NDA's impact on Protagonist's long-term performance and mentions that the stock might still be overvalued despite recent retreats.
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Protagonist Therapeutics announced that its President and CEO, Dinesh V. Patel, Ph.D., will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The presentation will cover the company's progress with two novel peptides, icotrokinra and rusfertide, which are in advanced Phase 3 clinical development with recent NDA submissions. Protagonist Therapeutics is a biopharmaceutical company focused on discovery through late-stage development, with a pipeline targeting various clinical indications.
